The rise of popular GLP-1 drugs for obesity management comes with substantial litigation risk. Increased use has sparked a wave of litigation in the United States, with over 2,190 lawsuits consolidated in a multidistrict litigation class action. Plaintiffs allege manufacturers failed to adequately warn of severe side effects, including gastroparesis (delayed stomach emptying), vision loss (notably NAION) and suicidal thoughts. Recent regulatory developments, including the European Medicines Agency’s mandate for updated warning labels, and new findings cited in the Journal of the American Medical Association regarding vision loss have shifted litigation focus towards vision-related claims. These regulatory actions may be used by plaintiffs as evidence of known risks. Gastroparesis claims now require confirmation by gastric emptying study, potentially excluding some cases. Overall, these product liability exposures are expected to increase, with continued volatility as regulatory scrutiny intensifies and as the multidistrict litigation progresses.